A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity

A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity

Submitted by admin on August 29, 2022 - 10:40am
Source: 
Fierce Pharma
News Tags: 
Novo Nordisk
semaglutide
NASH
Alzheimer's disease
Saxenda
obesity
Headline: 
A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity
snippet: 

​Novo Nordisk’s recent growth renaissance has arrived thanks in no small part to semaglutide—the GLP-1 molecule behind the company’s leading marketed trio of Ozempic, Rybelsus and Wegovy.

Do Not Allow Advertisers to Use My Personal information